体外膜肺氧合作为成人心脏移植直接桥接的应用
该研究利用美国器官共享网络2003至2016年数据,比较107例以体外膜肺氧合(ECMO)直接桥接心脏移植与6148例以连续流左心室辅助装置桥接的成人受者。ECMO组移植后90天和3年生存率均低于连续流左心室辅助装置组(90天73.1% vs 93.1%,3年67.4% vs 82.4%,P均<.001),倾向性匹配后90天生存率仍较低(74.8% vs 88.8%,P=.025);ECMO组中MELD-XI评分高者移植后生存差。
要点
- ECMO直接桥接心脏移植在成人中罕见,仅占25,168例受者的0.4%(107例)。
- ECMO组移植后90天和3年生存率均低于连续流左心室辅助装置组(P<.001)。
- ECMO组中MELD-XI评分>17者3年生存率仅49.5%,低于评分<13者的73.5%。
核心结论
- 以ECMO桥接心脏移植与早期和中期死亡率增加相关,尤其在MELD-XI评分高的患者中3年死亡率超过50%。
- 这些发现可能有助于为未来的器官分配政策提供信息。
研究设计与样本
- 利用美国器官共享网络提供的去标识化患者级数据,回顾性识别2003年至2016年间25,168例成人心脏移植受者。
- 其中107例(0.4%)以ECMO桥接,6148例(24.4%)以连续流左心室辅助装置桥接。
- 采用Kaplan-Meier分析和倾向性匹配队列分析比较两组移植后生存率。
- 在ECMO患者中采用多变量 logistic 回归和 Cox 回归分析90天和3年死亡的相关因素。
主要发现
- ECMO组患者较连续流左心室辅助装置组更年轻、功能状态严重受限比例更高、等待名单时间更短、机械通气比例更高。
- Kaplan-Meier分析显示ECMO组与连续流左心室辅助装置组移植后90天生存率分别为73.1% vs 93.1%(P<.001),3年生存率分别为67.4% vs 82.4%(P<.001)。
- 倾向性匹配队列分析显示ECMO组90天生存率仍较低(74.8% vs 88.8%,P=.025),3年生存率差异未达统计学显著(69.3% vs 82.2%,P=.054)。
- 在ECMO患者中,多变量分析显示MELD-XI评分是90天死亡(比值比1.94;95%CI 1.00-3.76;P=.050)和3年死亡(风险比1.47;95%CI 1.16-1.88;P=.002)的唯一贡献因素。
- ECMO支持的MELD-XI评分>17患者较MELD-XI评分<13患者移植后生存差:90天生存率54.4% vs 85.0%(P<.001),3年生存率49.5% vs 73.5%(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Venoarterial extracorporeal membrane oxygenation (ECMO) use as a bridge to transplant is extremely infrequent in adults. We investigated patient outcomes of the use of ECMO as bridge to transplant. METHODS: United Network of Organ Sharing provided de-identified patient-level data. Between 2003 and 2016, 25,168 adult recipients were identified. Of these, 107 (0.4%) were bridged with ECMO and 6148 (24.4%) were bridged with a continuous-flow left ventricular assist device. RESULTS: Patients in ECMO group were younger, more likely to have severely disabled functional status, shorter waitlist time, and were more frequently mechanically ventilated than were patients in the continuous-flow left ventricular assist device group. Kaplan-Meier analysis demonstrated estimated posttransplant survival of 73.1% versus 93.1% at 90 days (P < .001) and 67.4% versus 82.4% at 3 years (P < .001) in ECMO and continuous-flow left ventricular assist device groups, respectively. Analysis of a propensity-matched cohort still demonstrated a lower survival in ECMO group at 90 days (74.8% vs 88.8%; P = .025) and 3 years (69.3% vs 82.2%; P = .054). Among the ECMO patients, multivariable logistic and Cox regression analyses showed model for end-stage liver disease excluding international normalized ratio (MELD-XI) score to be the sole contributor to both 90-day (odds ratio, 1.94; 95% confidence interval, 1.00-3.76; P = .050) and 3-year mortality (hazard ratio, 1.47; 95% confidence interval, 1.16-1.88; P = .002). ECMO-supported patients with a high MELD-XI score (>17) were associated with poor posttransplant survival compared with those with a low MELD-XI score (<13) (90 day, 54.4% vs 85.0% [P < .001] and 3 year, 49.5% vs 73.5% [P < .001]). CONCLUSIONS: Bridge to transplant with ECMO was associated with increased early/mid-term mortality, especially in patients with a high MELD-XI score who demonstrated > 50% 3-year mortality. These findings may help to inform future organ allocation policies.
引用
- Fukuhara S, Takeda K, Kurlansky PA, et al. Extracorporeal membrane oxygenation as a direct bridge to heart transplantation in adults. J Thorac Cardiovasc Surg. 2017. PMID: 29361299. doi:10.1016/j.jtcvs.2017.10.152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。